{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:13:25Z","timestamp":1777709605390,"version":"3.51.4"},"reference-count":124,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018857","name":"International Myeloma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA276156"],"award-info":[{"award-number":["R01CA276156"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01CA225730"],"award-info":[{"award-number":["U01CA225730"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hoc.2023.12.016","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T15:54:17Z","timestamp":1706198057000},"page":"321-336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Proteasome Inhibitors in Multiple Myeloma"],"prefix":"10.1016","volume":"38","author":[{"given":"Constantine S.","family":"Mitsiades","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2023.12.016_bib1","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.12.016_bib2","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.016_bib3","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A\u00a0phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.12.016_bib4","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Assessment of Proteasome Inhibition for Extending Remissions I. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.12.016_bib5","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.016_bib6","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S1471-4914(02)02315-8","article-title":"Proteasome inhibition: a novel approach to cancer therapy","volume":"8","author":"Adams","year":"2002","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.hoc.2023.12.016_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1634\/theoncologist.7-1-9","article-title":"Development of the proteasome inhibitor PS-341","volume":"7","author":"Adams","year":"2002","journal-title":"Oncol"},{"key":"10.1016\/j.hoc.2023.12.016_bib8","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1081\/CNV-120030218","article-title":"Development of the proteasome inhibitor Velcade (Bortezomib)","volume":"22","author":"Adams","year":"2004","journal-title":"Cancer Invest"},{"key":"10.1016\/j.hoc.2023.12.016_bib9","first-page":"4996","article-title":"Proteasome inhibitor PS-341 inhibits human myeloma cell growth in\u00a0vivo and prolongs survival in a murine model","volume":"62","author":"LeBlanc","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.016_bib10","doi-asserted-by":"crossref","first-page":"14374","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2023.12.016_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2023.12.016_bib12","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","article-title":"Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma","volume":"29","author":"Larrayoz","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2023.12.016_bib14","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib15","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1038\/sj.onc.1208522","article-title":"Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors","volume":"24","author":"Hideshima","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.hoc.2023.12.016_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq5575","article-title":"Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma","volume":"8","author":"Sharma","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.hoc.2023.12.016_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41408-020-00393-0","article-title":"Downregulation of PA28alpha induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma","volume":"10","author":"Gu","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.12.016_bib18","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood-2003-01-0233","article-title":"NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma","volume":"102","author":"Catley","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib19","first-page":"6174","article-title":"Blockade of Hsp27 overcomes Bortezomib\/proteasome inhibitor PS-341 resistance in lymphoma cells","volume":"63","author":"Chauhan","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.016_bib20","doi-asserted-by":"crossref","first-page":"8386","DOI":"10.1038\/sj.onc.1207170","article-title":"Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma","volume":"22","author":"Hideshima","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.hoc.2023.12.016_bib21","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib22","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1182\/blood-2004-02-0547","article-title":"Targeting mitochondria to overcome conventional and bortezomib\/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells","volume":"104","author":"Chauhan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib23","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood-2003-08-2873","article-title":"The bortezomib\/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance","volume":"103","author":"Chauhan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib24","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2006-04-016055","article-title":"Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells","volume":"108","author":"Catley","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib25","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1078-0432.CCR-13-1657","article-title":"Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease","volume":"20","author":"Garcia-Gomez","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.016_bib26","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2013-05-504340","article-title":"Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy","volume":"123","author":"Mulligan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib27","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","article-title":"Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib","volume":"109","author":"Mulligan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib28","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1158\/0008-5472.CAN-06-4046","article-title":"Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling","volume":"67","author":"Chng","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.016_bib29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.clml.2021.05.017","article-title":"Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma","volume":"21","author":"Jakubowiak","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.hoc.2023.12.016_bib30","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A\u00a0phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib31","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bjh.15969","article-title":"Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed\/refractory multiple myeloma","volume":"186","author":"Jakubowiak","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2023.12.016_bib32","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/leu.2013.152","article-title":"Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study","volume":"27","author":"Jakubowiak","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.016_bib33","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","article-title":"Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Costa","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2023.12.016_bib34","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1182\/bloodadvances.2022008866","article-title":"Phase 1\/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma","volume":"7","author":"Derman","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2023.12.016_bib35","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s43018-023-00550-x","article-title":"Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias","volume":"4","author":"de Matos Simoes","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.hoc.2023.12.016_bib36","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2014-05-578732","article-title":"The Tao of myeloma","volume":"124","author":"Boise","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and processing of ubiquitin-protein conjugates by the proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.hoc.2023.12.016_bib38","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nature02263","article-title":"Protein degradation and protection against misfolded or damaged proteins","volume":"426","author":"Goldberg","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2023.12.016_bib39","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1146\/annurev.bi.43.070174.004155","article-title":"Intracellular protein degradation in mammalian and bacterial cells","volume":"43","author":"Goldberg","year":"1974","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.hoc.2023.12.016_bib40","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.aax3769","article-title":"Cellular quality control by the ubiquitin-proteasome system and autophagy","volume":"366","author":"Pohl","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.hoc.2023.12.016_bib41","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.chembiol.2021.04.007","article-title":"Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation","volume":"28","author":"Kannt","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.hoc.2023.12.016_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/nyas.14745","article-title":"Targeted protein degradation: from small molecules to complex organelles-a Keystone Symposia report","volume":"1510","author":"Cable","year":"2022","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.hoc.2023.12.016_bib43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41580-022-00543-1","article-title":"An expanded lexicon for the ubiquitin code","volume":"24","author":"Dikic","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.hoc.2023.12.016_bib44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nsmb.2780","article-title":"New insights into ubiquitin E3 ligase mechanism","volume":"21","author":"Berndsen","year":"2014","journal-title":"Nat Struct Mol Biol"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2023.12.016_bib45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","article-title":"The proteasome: structure, function, and role in the cell","volume":"29","author":"Adams","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.hoc.2023.12.016_bib46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41586-018-0736-4","article-title":"Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome","volume":"565","author":"Dong","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2023.12.016_bib47","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41590-018-0186-z","article-title":"The immunoproteasome and thymoproteasome: functions, evolution and human disease","volume":"19","author":"Murata","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.hoc.2023.12.016_bib48","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.016_bib49","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41375-019-0517-6","article-title":"Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma","volume":"33","author":"Landgren","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.016_bib50","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.016_bib51","first-page":"22","article-title":"Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism","author":"Wang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hoc.2023.12.016_bib52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev.pharmtox.46.120604.141300","article-title":"The proteasome and proteasome inhibitors in cancer therapy","volume":"46","author":"Voorhees","year":"2006","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.hoc.2023.12.016_bib53","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1309\/44HW-5YCJ-FLLP-3R56","article-title":"The proteasome: a new target for novel drug therapies","volume":"116","author":"Elliott","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hoc.2023.12.016_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/biom12010054","article-title":"Site-Specific Proteasome Inhibitors","volume":"12","author":"Kisselev","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.hoc.2023.12.016_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105537","article-title":"Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice","volume":"167","author":"Fogli","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.hoc.2023.12.016_bib56","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome Inhibitor Drugs","volume":"60","author":"Fricker","year":"2020","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.hoc.2023.12.016_bib57","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/dmd.112.047662","article-title":"Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib","volume":"41","author":"Wang","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.hoc.2023.12.016_bib58","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","article-title":"Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors","volume":"26","author":"Besse","year":"2019","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.hoc.2023.12.016_bib59","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib60","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a therapeutic target in multiple myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.hoc.2023.12.016_bib61","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","article-title":"The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition","volume":"113","author":"Bianchi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib62","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/sj.emboj.7601009","article-title":"Progressively impaired proteasomal capacity during terminal plasma cell differentiation","volume":"25","author":"Cenci","year":"2006","journal-title":"EMBO J"},{"key":"10.1016\/j.hoc.2023.12.016_bib63","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.molimm.2009.12.003","article-title":"CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells","volume":"47","author":"Masciarelli","year":"2010","journal-title":"Mol Immunol"},{"key":"10.1016\/j.hoc.2023.12.016_bib64","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.seminhematol.2012.04.005","article-title":"The proteasome in terminal plasma cell differentiation","volume":"49","author":"Cenci","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.hoc.2023.12.016_bib65","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/ni.2524","article-title":"Plasma cells require autophagy for sustainable immunoglobulin production","volume":"14","author":"Pengo","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.hoc.2023.12.016_bib66","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.016_bib67","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T\u00a0cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib68","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T\u00a0Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.016_bib69","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.12.016_bib70","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T\u00a0cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.016_bib71","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2023.12.016_bib72","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1021\/jacs.5b01876","article-title":"An anti-B cell maturation antigen bispecific antibody for multiple myeloma","volume":"137","author":"Ramadoss","year":"2015","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.hoc.2023.12.016_bib73","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2023.12.016_bib74","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2023.12.016_bib75","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2023.12.016_bib76","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.hoc.2023.12.016_bib77","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","article-title":"Anti-GPRC5D\/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma","volume":"18","author":"Kodama","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.hoc.2023.12.016_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T\u00a0cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hoc.2023.12.016_bib79","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","article-title":"Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","author":"Leung-Hagesteijn","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2023.12.016_bib80","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2023.12.016_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.756941","article-title":"Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study","volume":"12","author":"Walhelm","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.hoc.2023.12.016_bib82","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1177\/0961203317691371","article-title":"Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases","volume":"26","author":"Sjowall","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.hoc.2023.12.016_bib83","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.hoc.2023.12.016_bib84","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2023.12.016_bib85","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma","volume":"12","author":"Annunziata","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2023.12.016_bib86","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056132","article-title":"Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib","volume":"8","author":"Shabaneh","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.hoc.2023.12.016_bib87","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/bloodadvances.2018016360","article-title":"An inhibitor of proteasome beta2 sites sensitizes myeloma cells to immunoproteasome inhibitors","volume":"2","author":"Downey-Kopyscinski","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2023.12.016_bib88","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/bloodadvances.2020003820","article-title":"Multiple myeloma cells depend on the DDI2\/NRF1-mediated proteasome stress response for survival","volume":"6","author":"Chen","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2023.12.016_bib89","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-17239-3","article-title":"A\u00a0clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax","volume":"12","author":"Downey-Kopyscinski","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.hoc.2023.12.016_bib90","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2023.12.016_bib91","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1200\/JCO.2009.22.2679","article-title":"Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed\/refractory multiple myeloma","volume":"27","author":"Richardson","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.016_bib92","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood-2013-07-517276","article-title":"A\u00a0phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed\/refractory myeloma","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib93","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/leu.2011.256","article-title":"Impaired bortezomib binding to mutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells","volume":"26","author":"Franke","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.016_bib94","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/273180","article-title":"Inhibition of Nek2 by small molecules affects proteasome activity","volume":"2014","author":"Meng","year":"2014","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.hoc.2023.12.016_bib95","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.08153","article-title":"Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits","volume":"4","author":"Acosta-Alvear","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.hoc.2023.12.016_bib96","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1073\/pnas.1619067114","article-title":"Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers","volume":"114","author":"Tsvetkov","year":"2017","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2023.12.016_bib97","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41589-019-0291-9","article-title":"Mitochondrial metabolism promotes adaptation to proteotoxic stress","volume":"15","author":"Tsvetkov","year":"2019","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.hoc.2023.12.016_bib98","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15210","article-title":"Resistance to proteasome inhibitors and other targeted therapies in myeloma","volume":"182","author":"Wallington-Beddoe","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2023.12.016_bib99","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-3-030-38266-7_6","article-title":"Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma","volume":"1233","author":"Gonzalez-Santamarta","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.hoc.2023.12.016_bib100","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.3324\/haematol.2018.207704","article-title":"A\u00a0metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis","volume":"104","author":"Besse","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2023.12.016_bib101","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2017.212","article-title":"Carfilzomib resistance due to ABCB1\/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma","volume":"32","author":"Besse","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.016_bib102","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fendo.2018.00218","article-title":"Soluble and Cell-Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma","volume":"9","author":"Farrell","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.hoc.2023.12.016_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108059","article-title":"Mitochondrial Regulation of the 26S Proteasome","volume":"32","author":"Meul","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.hoc.2023.12.016_bib104","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/s41375-020-0989-4","article-title":"Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma","volume":"35","author":"Allmeroth","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.016_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27072201","article-title":"Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance","volume":"27","author":"Leonardo-Sousa","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.hoc.2023.12.016_bib106","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.chembiol.2022.06.010","article-title":"Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma","volume":"29","author":"Ferguson","year":"2022","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.hoc.2023.12.016_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020532","article-title":"Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma","volume":"15","author":"Haertle","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.hoc.2023.12.016_bib108","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1078-0432.CCR-22-1161","article-title":"Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma","volume":"29","author":"Haertle","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.016_bib109","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1182\/blood.2020005795","article-title":"MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015479","article-title":"The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97\/VCP inhibitory group","volume":"5","author":"Wang","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.hoc.2023.12.016_bib111","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1073\/pnas.0807611106","article-title":"ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells","volume":"106","author":"Wang","year":"2009","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2023.12.016_bib112","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41419-022-05421-4","article-title":"An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma","volume":"13","author":"Darawshi","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.hoc.2023.12.016_bib113","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","article-title":"Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing","volume":"27","author":"Cohen","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2023.12.016_bib114","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drup.2008.08.002","article-title":"Mechanisms of proteasome inhibitor action and resistance in cancer","volume":"11","author":"McConkey","year":"2008","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.hoc.2023.12.016_bib115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","article-title":"Molecular basis of resistance to proteasome inhibitors in hematological malignancies","volume":"18","author":"Niewerth","year":"2015","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.hoc.2023.12.016_bib116","first-page":"634","article-title":"Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?","volume":"4","author":"Bo Kim","year":"2021","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.hoc.2023.12.016_bib117","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.tips.2023.05.006","article-title":"Overcoming proteasome inhibitor resistance in the immunotherapy era","volume":"44","author":"Patino-Escobar","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.hoc.2023.12.016_bib118","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41375-018-0216-8","article-title":"Spectrum and functional validation of PSMB5 mutations in multiple myeloma","volume":"33","author":"Barrio","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.016_bib119","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10555-017-9699-4","article-title":"(Immuno)proteasomes as therapeutic target in acute leukemia","volume":"36","author":"Cloos","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.hoc.2023.12.016_bib120","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1124\/jpet.111.187542","volume":"341","author":"Verbrugge","year":"2012","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.hoc.2023.12.016_bib121","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/leu.2010.137","article-title":"Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress","volume":"24","author":"Ri","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.016_bib122","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.016_bib123","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2023.12.016_bib124","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1158\/0008-5472.CAN-05-2961","article-title":"Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells","volume":"66","author":"Nawrocki","year":"2006","journal-title":"Cancer Res"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:18:01Z","timestamp":1760591881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823001831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0889858823001831"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.016","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteasome Inhibitors in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}